Redirecting to deep profile of Vishal Rajput at Chemtatva Chiral Solutions (Ccs) Private Limited...
Click here to continueBelow are the verified contact details to help you connect directly:
Email: vis*****@che******.com
Mobile: 97596*****
Estimated Net Worth: ₹0 – ₹500+ Cr (approx. $0 – $60M)
- Vishal Rajput is the Founder and CEO of Chemtatva Chiral Solutions Private Limited, a position set to commence on February 1, 2024.
- Prior to establishing Chemtatva, Vishal served as the Vice President of Business Development at TCG Lifesciences Pvt Ltd. from March 2022 until January 2024, contributing to strategic growth initiatives within the organization.
- From December 2020 to March 2022, Vishal held the role of Head of Global CDMO Business for API and Formulations at SHILPA MEDICARE LTD, overseeing operations and developing business strategies across multiple markets.
- In a previous role as Associate General Manager of Global Business Development at Syngene International Limited from June 2019 to June 2020, Vishal led initiatives to expand the company's global outreach.
- Between April 2016 and June 2019, Vishal worked as a Senior API Specialist for Asia Pacific at Merck Life Science, where responsibilities included building client relationships and driving sales growth.
- Vishal began their career at Merck Life Science in February 2015 as a Business Development Manager for Process Solutions, providing insights that influenced future product offerings.
- In 2013, Vishal served as Group Leader at Neuland Laboratories Limited in Hyderabad, India, managing projects that contributed to portfolio development and strengthening market position.
- Prior experience includes a scientific leadership role at GVK Biosciences, serving as a team leader from July 2012 to November 2013, where direct contributions to scientific research were made.
- Vishal's career began as a Research Scientist at Jagsonpal Pharmaceuticals Limited from May 2005 to November 2005, providing foundational experience in pharmaceutical research and development.